Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model

Cancer Prevention Research

Volumn 2, Issue 2, 2009, Pages 175-184

  Abba, Martin C ^a   Hu, Yuhui ^a   Levy, Carla C ^a   Gaddis, Sally ^a   Kittrell, Frances S ^b   Hill, Jamal ^b   Bissonnette, Reid P ^c   Brown, Powel H ^b   Medina, Daniel ^b   Marcelo Aldaz, C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CELECOXIB; EARLY GROWTH RESPONSE FACTOR 1; GEFITINIB; GELSOLIN; PROTEIN P53; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 2; TUMOR PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE; TETRALIN DERIVATIVE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC VARIABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERIAL ANALYSIS OF GENE EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PRECANCER; UDDER;

ANIMALS; ANTICARCINOGENIC AGENTS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; PYRAZOLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; TETRAHYDRONAPHTHALENES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63249128577     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0104     Document Type: Article

References (37)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388 (Pubitemid 28439961)
2. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in post-menospausal women: results form the MORE randomized trial. Multiple Outcomes of Raloxifene evaluation. JAMA 1999;281:2189-2197 (Pubitemid 29275701)
3. Shen Q, Brown PH. Transgenic mouse models for the prevention of breast cancer. Mutat Res 2005;576:93-110.
4. Jerry DJ, Kittrell FS, Kuperwasser C, et al. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 2000;19:1052-1058 (Pubitemid 30153789)
5. Medina D, Kittrell FS, Shepard A, et al. Biological and genetic properties of the p53-null preneoplastic mammary epithelium. FASEB J 2002;16:881-883
6. Hu Y, Sun H, Drake J, et al. From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res 2004;64:7748-7755 (Pubitemid 39446906)
7. Narayanan BA. Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Current Cancer Drug Targets 2006;6:711-727
8. Medina D, Kittrell F, Hill J, Hilsenbeck S, Brown PH. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid baxarotene, tyrosine kinase inhibitor gefitinib and celecoxib. Cancer Prevent Res. 2009;2:168-174
9. Aldaz CM, Hu Y, Daniel R, Gaddis S, Kittrell F, Medina D. Serial analysis of gene expression in normal p53-null mammary epithelium. Oncogene 2002;21:6366-6376
10. Charpentier AH, Bednarek AK, Daniel RL, et al. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 2000;60:5977-5983
11. Audic S, Claverie J. The significance of digital gene expression profiles. Genome Res 1997;7:986-995 (Pubitemid 27487763)
12. Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
13. Dennis G, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:R60.
14. Smid M, Dorssers LCJ, Jenster G. Venn Mapping: clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes. Bioinformatic 2003;19:2065-2071 (Pubitemid 37408157)
15. Wu K, Kim H, Rodriguez JL, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 2002;11:467-474
16. Wu K, Zhang Y, Xu X, et al. The retinoid X receptor-selective retinoid, LGD1069, prevent the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-6380 (Pubitemid 35364089)
17. Kim HT, Kong G, Denardo D, et al. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res 2006;66:12009-12018 (Pubitemid 46094215)
18. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-8895 (Pubitemid 34013905)
19. Lu C, Speers C, Zhang Y, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 2003;95:1825-1833 (Pubitemid 38054683)
20. Howe LR, Dannenberg AJ. COX-2 inhibitors for the prevention of breast cancer. J Mamm Gland Biol Neoplas 2003;8:31-43. (Pubitemid 38129949)
21. Yoshioka K, Deng T, Cavigelli M, Karin M. Antitumor promotion by phenolic antioxidants: inhibition of AP-1 activity through induction of Fra expression. Proc Natl Acad Sci U S A 1995;92:4972-4976
22. Rezzonico R, Loubat A, Lallemand D, et al. Cyclic AMP stimulates a JunD/Fra-2 AP-1 complex and inhibits the proliferation of interleukin-6- dependent cell lines. Oncogene 1995;11:1069-1078
23. Rutberg SE, Saez E, Lo S, et al. Opposing activities of c-Fos and Fra-2 on AP-1 regulated transcriptional activity in mouse keratinocytes induced to differentiate by calcium and phorbol esters. Oncogene 1997;15:1337-1346 (Pubitemid 27429750)
24. Sharma SC, Richards JS. Regulation of AP1 (Jun/Fos) factor expression and activation in ovarian granulose cells. Relation of JunD and Fra2 to terminal differentiation. J Biol Chem 2000;275:33718-33728
25. Huang RP, Liu C, Fan Y, Mercola D, Adamson ED. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res 1995;55:5054-5062
26. Huang RP, Fan Y, de Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlate with tumor formation. Int J Cancer 1997;72:102-109 (Pubitemid 27314646)
27. Ronski K, Sanders M, Burleson JA, Moyo V, Benn P, Fange M. Early growth response gene 1 (EGR1) is deleted in estrogen receptor-negative human breast carcinoma. Cancer 2005;104:925-930 (Pubitemid 41170218)
28. Dong Y, Asch HL, Ying A, Asch BB. Molecular mechanism of trasncriptonal repression of gelsolin in human breast cancer cells. Exp Cell Res 2002;276:328-336
29. Asch HL, Winston JS, Edge SB, Stamper PC, Asch BB. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res Treat 1999;55:179-188
30. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB. Down-regulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 2001;65:11-21.
31. Joyce JA, Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 2004;3:1516-1619 (Pubitemid 40521403)
32. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005;52:1-9. (Pubitemid 40502564)
33. Wang B, Sun J, Kitamoto S, et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 2006;281:6020-6029 (Pubitemid 43847703)
34. Dear TN, Meier NT, Hunn M, Boehm T. Gene structure, chromosomal localization and expression pattern of Capn12, a new member of the calpain large subunit gene family. Genomics 2000;68:152-160
35. Arne J, Rolli V, Schreiber V, et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 1999;274:17860-17868 (Pubitemid 129519145)
36. De Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7307 (Pubitemid 27345310)
37. Masson M, Niedergang C, Schreiber V, Muller S, Murcia JM, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18:3563-3571 (Pubitemid 28240528)